Literature DB >> 8419069

ANCA and associated diseases: immunodiagnostic and pathogenetic aspects.

W L Gross1, W H Schmitt, E Csernok.   

Abstract

The past decade has seen an explosion of data on the new group of autoantibodies known collectively as ANCA (anti-neutrophil cytoplasmic antibodies). ANCA are specific for granule proteins of granulocytes and monocytes and induce distinct fluorescence patterns, e.g. the cytoplasmic (classic) cANCA and the perinuclear pANCA. cANCA is induced by antibodies directed against Proteinase 3 (PR3; PR3-ANCA) in about 90% of all ANCA-positive sera, and pANCA is induced by antibodies against myeloperoxidase (MPO; MPO-ANCA) in about 40%. A further staining pattern, which does not have a clear cut association with a distinct granule protein, is sometimes seen in chronic inflammatory bowel diseases. PR3-ANCA are serological markers for Wegener's granulomatosis (WG) and MPO-ANCA are associated with certain subtypes of primary vasculitides. Evidence exists that both the autoantigen and ANCA participate in the pathogenesis of at least the group of 'ANCA-associated vasculitides'.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8419069      PMCID: PMC1554662          DOI: 10.1111/j.1365-2249.1993.tb03345.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  96 in total

Review 1.  Wegener's granulomatosis occurring in siblings.

Authors:  E M Hay; M Beaman; A J Ralston; P Ackrill; R M Bernstein; P J Holt
Journal:  Br J Rheumatol       Date:  1991-04

Review 2.  The do-not-resuscitate order. Ethical and legal imperative or medical decision?

Authors:  G L Snider
Journal:  Am Rev Respir Dis       Date:  1991-03

3.  Antineutrophil cytoplasmic antibodies, cystic fibrosis, and infection.

Authors:  J Efthimiou; G Spickett; D Lane; A Thompson
Journal:  Lancet       Date:  1991-04-27       Impact factor: 79.321

4.  Autoantibodies to endothelial cells and neutrophil cytoplasmic antigens in systemic vasculitis.

Authors:  G Frampton; D R Jayne; G J Perry; C M Lockwood; J S Cameron
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

Review 5.  Vasculitis as a paraneoplastic syndrome. Report of 11 cases and review of the literature.

Authors:  J Sánchez-Guerrero; S Gutiérrez-Ureña; A Vidaller; E Reyes; A Iglesias; D Alarcón-Segovia
Journal:  J Rheumatol       Date:  1990-11       Impact factor: 4.666

6.  Mycobacteria and human autoimmune disease: direct evidence of cross-reactivity between human lactoferrin and the 65-kilodalton protein of tubercle and leprosy bacilli.

Authors:  N Esaguy; A P Aguas; J D van Embden; M T Silva
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

7.  The specificity of anti-neutrophil cytoplasm autoantibodies in systemic vasculitides.

Authors:  K N Lai; D R Jayne; A Brownlee; C M Lockwood
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

8.  Titration of antibodies against neutrophil cytoplasmic antigens is useful in monitoring disease activity in systemic vasculitides.

Authors:  W Egner; H M Chapel
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

9.  Cloning of cDNA for proteinase 3: a serine protease, antibiotic, and autoantigen from human neutrophils.

Authors:  D Campanelli; M Melchior; Y Fu; M Nakata; H Shuman; C Nathan; J E Gabay
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

10.  Systemic vasculitis in the 1980s--is there an increasing incidence of Wegener's granulomatosis and microscopic polyarteritis?

Authors:  M Andrews; M Edmunds; A Campbell; J Walls; J Feehally
Journal:  J R Coll Physicians Lond       Date:  1990-10
View more
  65 in total

1.  Granulocyte-macrophage colony-stimulating factor (GM-CSF) but not granulocyte colony-stimulating factor (G-CSF) induces plasma membrane expression of proteinase 3 (PR3) on neutrophils in vitro.

Authors:  B Hellmich; E Csernok; A Trabandt; W L Gross; M Ernst
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

Review 2.  Small vessel vasculitis of the lung.

Authors:  M I Schwarz; K K Brown
Journal:  Thorax       Date:  2000-06       Impact factor: 9.139

Review 3.  Methods for the detection of anti-neutrophil cytoplasmic antibodies. Recommendations for clinical use of ANCA serology and laboratory efforts to optimize the informative value of ANCA test results.

Authors:  A Wiik
Journal:  Springer Semin Immunopathol       Date:  2001

4.  ELISA is the superior method for detecting antineutrophil cytoplasmic antibodies in the diagnosis of systemic necrotising vasculitis.

Authors:  A Harris; G Chang; M Vadas; D Gillis
Journal:  J Clin Pathol       Date:  1999-09       Impact factor: 3.411

5.  [Bactericidal permeability increasing protein (BPI-ANCA marked chronic inflammatory bowel diseases and hepatobiliary diseases].

Authors:  A Schnabel; E Csernok; H Schultz; M Stoffel; C Herzberg; S F Carroll; W L Gross
Journal:  Med Klin (Munich)       Date:  1997-07-15

Review 6.  [Pulmonary-renal syndrome].

Authors:  K de Groot; A Schnabel
Journal:  Internist (Berl)       Date:  2005-07       Impact factor: 0.743

7.  Use of immunofluorescence and confocal laser scanning microscopy in identifying rare cases of anti-neutrophil cytoplasmic antibodies (ANCA) showing dual specificities to myeloperoxidase and proteinase3.

Authors:  S S Badakere; Vandana D Pradhan; A F Almeida; Aruna R Pawar
Journal:  J Fluoresc       Date:  2004-07       Impact factor: 2.217

8.  Invasive amoebiasis is associated with the development of anti-neutrophil cytoplasmic antibody.

Authors:  D J Pudifin; J Duursma; V Gathiram; T F Jackson
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

9.  Formalin fixation and patterns of antineutrophil cytoplasmic antibodies.

Authors:  G P Spickett; V Broomhead
Journal:  J Clin Pathol       Date:  1995-01       Impact factor: 3.411

10.  Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo.

Authors:  E Csernok; M Ernst; W Schmitt; D F Bainton; W L Gross
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.